Alumis Inc. (NASDAQ:ALMS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Alumis Inc. (NASDAQ:ALMS) have been given a consensus rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $39.60.

A number of research analysts have issued reports on ALMS shares. Stifel Nicolaus began coverage on shares of Alumis in a research note on Wednesday, February 25th. They set a “buy” rating and a $44.00 price target on the stock. Chardan Capital lifted their price objective on shares of Alumis from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, March 20th. Morgan Stanley boosted their price objective on shares of Alumis from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, March 20th. Oppenheimer reissued an “outperform” rating and issued a $50.00 target price on shares of Alumis in a research report on Tuesday, January 6th. Finally, Wall Street Zen raised Alumis from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th.

Alumis Stock Performance

Shares of ALMS stock opened at $24.81 on Thursday. Alumis has a fifty-two week low of $2.76 and a fifty-two week high of $30.60. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -8.11 and a beta of -2.15. The stock’s 50-day simple moving average is $26.51 and its 200-day simple moving average is $14.19.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The company had revenue of $1.93 million during the quarter, compared to analysts’ expectations of $2.75 million. Alumis had a negative net margin of 1,011.75% and a negative return on equity of 116.97%. As a group, equities analysts forecast that Alumis will post -8.51 earnings per share for the current year.

Insider Transactions at Alumis

In other news, Director Srinivas Akkaraju acquired 588,235 shares of Alumis stock in a transaction dated Friday, January 9th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the purchase, the director directly owned 1,853,488 shares in the company, valued at $31,509,296. This trade represents a 46.49% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Foresite Labs, Llc bought 411,764 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were purchased at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the acquisition, the insider directly owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. This trade represents a 7.78% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 1,823,527 shares of company stock valued at $30,999,959. 40.70% of the stock is owned by company insiders.

Institutional Trading of Alumis

Several large investors have recently made changes to their positions in the business. Ieq Capital LLC increased its stake in shares of Alumis by 4.1% in the fourth quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock worth $170,000 after acquiring an additional 690 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Alumis by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after purchasing an additional 979 shares during the period. ProShare Advisors LLC lifted its position in Alumis by 12.4% during the fourth quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock valued at $143,000 after purchasing an additional 1,618 shares during the period. Stoneridge Investment Partners LLC boosted its holdings in Alumis by 8.1% in the third quarter. Stoneridge Investment Partners LLC now owns 29,535 shares of the company’s stock valued at $118,000 after purchasing an additional 2,210 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after purchasing an additional 2,949 shares during the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.